Analysis of Height Indexes of Girls with Turner Syndrome Depending on Karyotype in Ukrainian Population

Objective: to determine the parameters of stature and bone age in girls with Turner syndrome (TS) in Ukrainian population depending on the age and karyotype, the final height compared with healthy girls, as well as the state of somatotropic pituitary function in girls with TS. Materials and methods. A retrospective analysis of 502 registration cards of girls with TS aged 11 months to 17 years inclusively has been carried out for a period from 2004 to 2014. In-depth examination was conducted in children who underwent outpatient or inpatient treatment in National children’s specialized hospital «Mother and child healthcare» and Ukrainian scientific and practical centre for endocrine surgery, transplantation of endocrine organs and tissues. We have determined physical development of a child, bone age, presence of growth failure, level of insulin-like growth factor 1 (IGF-1). To compare growth performance of children with TS and healthy girls in the general population, we used the results of a survey of the physical development of 525 somatically healthy girls with normal female karyotype aged 10 months to 17 years inclusively (the control group). Results. The difference in height in girls with TS and somatically healthy girls with normal female karyotype was significant (p < 0.05) in all the age groups older than one year, increased with age, the maximum was in adolescence. The degree of growth retardation in girls with TS averages –3.1 ± 1.1 SD with maximum delay in 14 years. Bone age in girls with TS is delayed in all age groups, with a maximum difference with real age in 17 years. No significant difference in indicators of growth, bone age, level of stimulated growth hormone and IGF-1in girls with the TS with different karyotype (p > 0.05) is observed, which indicates that the karyotype formula does not affect these figures. Most of the girls with TS have a normal somatotropic function, but 35.7 % have a partial or complete deficiency of growth hormone